Answers are grounded in this paper and cite their sources.
Accurate non-invasive assessment of PD-L1 expression and function remains challenging due to tumor heterogeneity and the limitations of conventional biopsy-based studies. Here, we present a modular platform based on atezolizumab for PD-L1 imaging and radiopharmaceutical evaluation in melanoma models. Atezolizumab was functionalized with trans-cyclooctene to allow rapid and selective conjugation, via inverse-demand Diels–Alder, with 99mTc-HYNIC-tetrazine probes, generating in situ a SPECT probe for in vivo studies. In a syngeneic C57BL/6J model with Tm1 cells, pretargeting allowed tumor detection at 4 h with heterogeneous intratumoral uptake; a directly labeled antibody evaluated at the same time point is reported as a reference. Cy5-tetrazine-enabled fluorescence labeling was used for in vitro studies, i.e., flow cytometry and quantitative analysis of PD-L1 status under basal and interferon-γ-stimulated conditions. To analyze PD-L1 as a target for radiotherapy, a conjugate of atezolizumab with lutetium-177, via a DOTA chelator, was developed and evaluated in vitro: at 0.55 MBq, it reduced Tm1 cell viability more than free 177LuCl3, with a greater effect after interferon-γ stimulation, and the effect was further increased in combination with a PARP inhibitor. Using the same antibody for imaging and radionuclide-based cytotoxicity suggests a potential theranostic application, to be validated in vivo. This work describes a modular platform for PD-L1 interrogation that supports further radiopharmaceutical development.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: